Biodexa Pharmaceuticals Plc (BDRX)

Compare

1.5400

+0.3400

+(28.33%)

At close: April 2 at 4:00:01 PM EDT

1.4800

-0.06

(-3.90%)

After hours: April 2 at 7:59:16 PM EDT

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, ...

ACCESS Newswire 14 days ago

BDRX
+28.33%
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million Company match Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical ne

GlobeNewswire 23 days ago

BDRX
+28.33%
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs

GlobeNewswire 27 days ago

BDRX
+28.33%
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that the U.S. Patent

GlobeNewswire last month

BDRX
+28.33%
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting com

GlobeNewswire last month

HGRAF

AEMD

GOSS
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases wit

GlobeNewswire last month

BDRX
+28.33%
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration ...

ACCESS Newswire last month

BDRX
+28.33%
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and

GlobeNewswire last month

BDRX
+28.33%
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: “I am delig

GlobeNewswire 2 months ago

BDRX
+28.33%
Result of General Meeting

November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, both resolutions put to the Company’s shareholders were duly passed. The full text of, inter alia, the resolutions

GlobeNewswire 4 months ago

BDRX
+28.33%
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming ...

ACCESS Newswire 4 months ago

BDRX
+28.33%
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that the Company has been formally notified that the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company has regained comp

GlobeNewswire 4 months ago

BDRX
+28.33%
Notice of General Meeting

November 7, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 22 November 2024 at 13:00 GMT was posted to shareholders yesterday. The Board of Dire

GlobeNewswire 4 months ago

BDRX
+28.33%
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival CARDIFF, UK / ACCESSWIRE / October 17, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical stage ...

ACCESS Newswire 5 months ago

BDRX
+28.33%
Biodexa Announces Successful Appeal of Nasdaq Delisting

Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that a Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for an extension of time to demonstrate compliance with the $1.00 minimum bid price requirement

GlobeNewswire 5 months ago

BDRX
+28.33%
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with Published Survival Rates Results Build on MTX110’s Performance in Two Phase 1 Studies in Diffuse Midline Glioma Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with

GlobeNewswire 5 months ago

BDRX
+28.33%
Interim results for the six months ended June 30, 2024

September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2024 which will also be made available on the Company’s website at www.biodexaph

GlobeNewswire 6 months ago

BDRX
+28.33%
ADR Ratio Change

September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing four hundred (400) ordinary shares, to the new ratio of one (1) ADR representing ten thousand

GlobeNewswire 6 months ago

BDRX
+28.33%
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantFunds to Advance Development of Phase 3 Asset Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces it made the final match payment with respect to a $17

GlobeNewswire 6 months ago

BDRX
+28.33%
Receipt of Nasdaq Delisting Determination - Plans to Appeal

August 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Receipt of Nasdaq Delisting Determination Plans to Appeal Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that on August 27, 2024, it received a Staff Determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Ma

GlobeNewswire 6 months ago

BDRX
+28.33%

Performance Overview

Return	BDRX	DAX P (^GDAXI)
YTD	-61.98%	+12.47%
1-Year	-95.78%	+22.47%
3-Year	-100.00%	+54.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biodexa Pharmaceuticals Plc (BDRX)

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Result of General Meeting

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Notice of General Meeting

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

ADR Ratio Change

Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Performance Overview